2026 · 2nd Quarter (Apr 1 - June 30)
Filed by ARTEMIS POLICY GROUP LLC.
Open official filingSource-reported fields
Literal source text
Issues related to reimbursement for hemophilia services and treatments in Medicare Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of Medicaid Community Engagement requirements
Literal federal measure citations: H.R. 1
Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans Policies related to co-pay accumulators, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers: comments on proposed rules re PBM transparency (EBSA-2026-0001) and prior authorization for prescription drugs (CMS-0062-P). Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs
Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599
Literal federal measure citations: HR 9599
Funding for federal hemophilia programs at CDC and HRSA for FY27 Funding and staffing for the CDC Division of Blood Disorders and Public Health Genomics
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
